Antisense- and RNA interference-based therapeutic strategies in allergy
- 1 October 2005
- journal article
- review article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 9 (4) , 840-853
Abstract
Modern therapeutic methods for manipulation of gene expression in allergic diseases have been receiving increased attention in the emerging era of functional genomics. With the growing application of gene silencing technologies, pharmacological modulation of translation represents a great advance in molecular therapy for allergy. Several strategies for sequence‐specific post‐transcriptional inhibition of gene expression can be distinguished: antisense oligonucleotides (AS‐ONs), ribozymes (RZs), DNA enzymes (DNAzymes), and RNA interference (RNAi) triggered by small interfering RNAs (siRNAs). Potential anti‐mRNA drugs in asthma and other allergic disorders may be targeted to cell surface receptors (adenosine A1 receptor, high‐affinity receptor Fc‐RI‐α, cytokine receptors), adhesion molecules and ligands (ICAM‐1, VLA‐4), ion channels (calcium‐dependent chloride channel‐1), cytokines and related factors (IL‐4, IL‐5, IL‐13, SCF, TNF‐α, TGF‐β1), intracellular signal transduction molecules, such as tyrosine‐protein kinases (Syk, Lyn, Btk), serine/threonine‐protein kinases (p38 α MAP kinase, Raf‐1), non‐kinase signaling proteins (RasGRP4), and transcription factors involved in Th2 differentiation and allergic inflammation (STAT‐6, GATA‐3, NF‐kB). The challenge to scientists is to determine which of the candidate targets warrants investment of time and resources. New‐generation respirable AS‐ONs, external guide sequence ribozymes, and RNA interference‐based therapies have the potential to satisfy unmet needs in allergy treatment, acting at a more proximal level to a key etiopathogenetic molecular process, represented by abnormal expression of genes. Moreover, antisense and siRNA technologies imply a more rational design of new drugs for allergy.Keywords
This publication has 72 references indexed in Scilit:
- Inhibition of the Expression of the Human RNase P Protein Subunits Rpp21, Rpp25, Rpp29 by External Guide Sequences (EGSs) and siRNAJournal of Molecular Biology, 2004
- Approaches for the sequence-specific knockdown of mRNANature Biotechnology, 2003
- Inhibition of GM-CSF Receptor Function by Stable RNA Interference in a NOD/SCID Mouse Hematopoietic Stem Cell Transplantation ModelOligonucleotides, 2003
- New asthma drugs acting on gene expressionJournal of Cellular and Molecular Medicine, 2003
- Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4Journal of Allergy and Clinical Immunology, 2003
- Association of the ADAM33 gene with asthma and bronchial hyperresponsivenessNature, 2002
- Discovery and Development of Respirable Antisense Therapeutics for AsthmaAntisense and Nucleic Acid Drug Development, 2002
- Lyn, Jak2, and Raf-1 Kinases Are Critical for the Antiapoptotic Effect of Interleukin 5, whereas only Raf-1 Kinase Is Essential for Eosinophil Activation and DegranulationJournal of Experimental Medicine, 1998
- Specific inhibition of immunoglobulin E‐mediated allergic reaction using antisense FcεRIα oligodeoxynucleotidesImmunology, 1998
- Antisense oligonucleotides to interleukin‐4 regulate IgE and IgG2a production by spleen cells from Nippostrongylus brasiliensis‐infected ratsEuropean Journal of Immunology, 1993